Akorn Receives FDA Warning and 4 Must-See Stock Analyses
Health Care REIT’s (NYSE:HCN) portfolio modifications should allow its earnings and cash flow growth to speed up more quickly than those of its peers, says RBC Capital. The firm thus anticipates that the stock’s multiple will rise over time and it keeps an Outperform rating.
Noble Energy (NYSE:NBL) shares are recommended by Credit Suisse prior to potential catalysts which include a New Ventures update on Thursday, third quarter commentary, and its analyst day early in December. The stocks are rated Outperform along with an $103 price target.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
MDC Partners (NASDAQ:MDCA) sees RBC Capital maintain its Outperform as the analysts find the shares attractive due to valuation. Additionally, the firm’s margins are thought to have risen in the third quarter and its investments could become accretive in the second half of 2012 and its fiscal year 2013.
Akorn’s (NASDAQ:AKRX) warning letter from the FDA is specific only to generic pilocarpine and cited no manufacturing deficiencies, says Piper Jaffray, which thinks it’s possible that Akorn might remove the product from the market, but also notes that the firm began shipping it only a few months ago and thus far has seen minimal sales. However, the analyst believes that the letter is no cause for alarm and still sees Akorn shares as attractive. Piper maintains its Overweight along with a $21 price target.
Deckers Outdoor Corporation (NASDAQ:DECK) has its estimates cut by Canaccord, thanks to recent UGG price cuts, growing competitive threats from Tom’s and Sorel brands and predictions that the firm will decrease its 2012 guidance. The shares are rated Hold.
Don’t Miss: Wal-Mart vs Amazon: The Battle Continues.